This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.86% per year. These returns cover a period from January 1, 1988 through February 2, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
pharmaceuticals: Archive
Johnson & Johnson vs. AbbVie: A Growth Showdown Amid Patent Cliffs
by Kinjel Shah
JNJ's diversified model, $32B R&D push and 48% stock surge in a year raise the stakes in its battle with ABBV for healthcare dominance.
JNJPositive Net Change ABBVPositive Net Change
pharmaceuticals
Bull of the Day: Cardinal Health (CAH)
by Bryan Hayes
This company serves nearly 90% of US hospitals and delivers more than 43,000 pharmaceutical shipments daily.
CAHPositive Net Change
cancer dividends earnings hospitals investing medical medical-devices oncology-screening pharmaceuticals smart-health
Merck vs. Bristol Myers: Which Pharma Stock Is a Better Pick in 2026?
by Ekta Bagri
BMY edges past MRK as generic headwinds bite, but new drug launches, cost cuts and a stronger 2026 outlook tilt the investment case in its favor.
BMYPositive Net Change MRKPositive Net Change
biotechnology biotechs medical pharmaceuticals
Genomics Stocks That Deserve a Place in Your Portfolio in 2026
by Ekta Bagri
Genomics and synthetic biology are reshaping healthcare, as rapid DNA sequencing advances power personalized medicine and strong market growth.
ILMNPositive Net Change BEAMNegative Net Change PACBNegative Net Change CRSPNegative Net Change SANANegative Net Change CRBUNegative Net Change
biotechnology biotechs gene-editing genetics genomics medical pharmaceuticals
AstraZeneca vs. Pfizer: Which Pharma Giant Has the Edge in 2026?
by Kinjel Shah
AZN's stronger growth outlook and 2030 revenue target may outshine PFE's yield and cheaper valuation.
AZNPositive Net Change PFEPositive Net Change
pharmaceuticals
Insmed Lags on Q4 Earnings, Stock Gains on 2026 Brinsupri Sales View
by Zacks Equity Research
INSM shares jump 7% as Brinsupri sales surge and 2026 outlook calls for at least $1B, despite a wider Q4 loss and rising expenses.
INSMNegative Net Change CSTLNegative Net Change HRMYNegative Net Change
biotechs earnings medical pharmaceuticals
Madrigal Q4 Earnings Miss, MASH Drug Sales Drive Top Line, Stock Down
by Zacks Equity Research
MDGL swings to a wider Q4 loss as expenses surge, but Rezdiffra sales top estimates and fuel revenue growth. The stock slides 11% in response to the mixed nature of the results.
MDGLNegative Net Change CSTLNegative Net Change HRMYNegative Net Change IMCRPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Will Immunology Drugs Continue to Drive AbbVie's Top Line in 2026?
by Sundeep Ganoria
ABBV's Skyrizi and Rinvoq drove more than 40% growth in 2025. Can these immunology blockbusters power double-digit gains again in 2026?
JNJPositive Net Change LLYPositive Net Change ABBVPositive Net Change
biotechs medical pharmaceuticals
BHC Stock Down on Q4 Earnings Miss, Salix Drives Revenue Growth
by Zacks Equity Research
Bausch stock slips as Q4 EPS misses despite 9% revenue growth, strong Salix and Bausch + Lomb gains, and an upbeat 2026 sales outlook.
ALKSNegative Net Change BHCNegative Net Change CSTLNegative Net Change HRMYNegative Net Change
biotechnology biotechs medical pharmaceuticals
Moderna Stock Jumps After FDA Reverses Course on Flu Shot
by Zacks Equity Research
MRNA stock rises 6% as the FDA agrees to review its flu vaccine filing after a surprise reversal, with a decision expected by Aug. 5, 2026.
SNYPositive Net Change GSKPositive Net Change MRNAPositive Net Change
biotechs medical messenger-rna pharmaceuticals vaccines